Table 2.:
Treatment Emergent Adverse Events Regardless of Attribution
| ADVERSE EVENTS (N=47) | Grade | ||||||
|---|---|---|---|---|---|---|---|
| 1 (N) | 2 (N) | 3 (N) | 4 (N) | 5 (N) | Total N (%) | ||
| Anemia | 11 | 8 | 6 | 1 | 0 | 26 | 55% |
| Platelet count decreased | 11 | 3 | 4 | 2 | 0 | 20 | 43% |
| Fatigue | 8 | 8 | 2 | 0 | 0 | 18 | 38% |
| Nausea | 12 | 1 | 3 | 0 | 0 | 16 | 34% |
| Lymphocyte count decreased | 4 | 3 | 4 | 0 | 0 | 11 | 23% |
| White blood cell decreased | 5 | 2 | 1 | 0 | 0 | 8 | 17% |
| Vomiting | 4 | 2 | 1 | 0 | 0 | 7 | 15% |
| Hypoalbuminemia | 1 | 2 | 1 | 0 | 0 | 4 | 9% |
| Hyponatremia | 2 | 0 | 1 | 1 | 0 | 4 | 9% |
| Hypertension | 0 | 2 | 1 | 0 | 0 | 3 | 6% |
| Neutrophil count decreased | 1 | 1 | 1 | 0 | 0 | 3 | 6% |
| ALT increased | 1 | 0 | 1 | 0 | 0 | 2 | 4% |
| AST increased | 0 | 1 | 1 | 0 | 0 | 2 | 4% |
| Dehydration | 0 | 1 | 1 | 0 | 0 | 2 | 4% |
| Generalized muscle weakness | 0 | 1 | 1 | 0 | 0 | 2 | 4% |
| Dyspnea | 0 | 0 | 1 | 0 | 0 | 1 | 2% |
| Hypotension | 0 | 0 | 1 | 0 | 0 | 1 | 2% |
| Hypoxia | 0 | 0 | 0 | 1 | 0 | 1 | 2% |
| Lung infection | 0 | 0 | 0 | 1 | 0 | 1 | 2% |
| Respiratory failure | 0 | 0 | 0 | 0 | 1 | 1 | 2% |
| Sepsis | 0 | 0 | 0 | 1 | 0 | 1 | 2% |
| Wound infection | 0 | 0 | 1 | 0 | 0 | 1 | 2% |
| Maximum Grade Any Adverse Event | 14 | 11 | 14 | 4 | 1 | ||